20:23 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
21:18 , Jul 31, 2018 |  BC Innovations  |  Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
21:59 , May 25, 2018 |  BC Extra  |  Preclinical News

Activating astrocytes to enhance memory

In a paper published in Cell , researchers at The Hebrew University of Jerusalem showed that activating astrocytes in the hippocampus, rather than direct neuronal activation, could improve memory. Previous studies have shown that astrocytes...
19:36 , Dec 6, 2016 |  BC Innovations  |  Distillery Techniques

Imaging

TECHNOLOGY: PET A clozapine-based PET imaging agent that binds DREADD-expressing neurons could help monitor the engraftment of neuronal transplants for neurological diseases. The PET agent consisted of 11 C radionuclide-labeled clozapine-N-oxide, which has a binding...
07:00 , Apr 11, 2016 |  BioCentury  |  Regulation

Tolerable uncertainty

Acadia Pharmaceuticals Inc. may have found a sensitive endpoint for Nuplazid pimavanserin in a condition lacking good measures by adapting a validated but broader scale. Although an FDA advisory committee was uncertain how much real-world...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Neurology INDICATION: Parkinson's disease (PD) Mouse studies suggest inhibiting thalamostriatal terminal activity could help treat Parkinson's disease (PD). Levels of thalamic input to indirect-pathway and direct-pathway medium spiny neurons (MSNs) were higher and lower, respectively,...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Oncothyreon, Braeburn deal

Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia. Braeburn plans to develop ATI-9242 into a long-acting...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Jazz Pharmaceuticals sales and marketing update

Jazz launched Versacloz clozapine in the U.S. to treat severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. Versacloz has a wholesale acquisition cost of $734.14...